{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:03:12Z","timestamp":1793430192320,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.canlet.2025.217900","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T11:11:47Z","timestamp":1751454707000},"page":"217900","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Drug-tolerant persisting polyploid giant cancer cells mediate resistance to HER2-targeting antibody-drug conjugates"],"prefix":"10.1016","volume":"630","author":[{"given":"Narjes","family":"Yazdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Pourjamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riku","family":"Katainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juho","family":"V\u00e4\u00e4n\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"V\u00e4h\u00e4rautio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorma","family":"Isola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Kempas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Le Joncour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirjo","family":"Laakkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikki","family":"Joensuu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9585-7669","authenticated-orcid":false,"given":"Mark","family":"Barok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2025.217900_bib1","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41571-023-00815-5","article-title":"Drug-tolerant persister cells in cancer: the cutting edges and future directions","volume":"20","author":"Pu","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217900_bib2","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.cell.2020.10.027","article-title":"Persistent cancer cells: the deadly survivors","volume":"183","author":"Shen","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.217900_bib3","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2021.07.017","article-title":"Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy","volume":"16","author":"Mikubo","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2025.217900_bib4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.canlet.2025.217900_bib5","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","article-title":"HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target","volume":"19","author":"Gravalos","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217900_bib6","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217900_bib7","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2012.44.9694","article-title":"Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"31","author":"Hurvitz","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217900_bib8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-Positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217900_bib9","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-Positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217900_bib10","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1470-2045(17)30111-0","article-title":"Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study","volume":"18","author":"Thuss-Patience","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.217900_bib11","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-Positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217900_bib12","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andre","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2025.217900_bib13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"issue":"9_Supplement","key":"10.1016\/j.canlet.2025.217900_bib14","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PO1-04-01","article-title":"Phase 1 dose escalation study of ARX788, a next-generation anti-HER2 antibody drug conjugate, in heavily pretreated breast cancer patients","volume":"84","author":"Frentzas","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.217900_bib15","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1158\/1535-7163.MCT-19-0207","article-title":"A novel Anti-HER2 antibody-drug conjugate XMT-1522 for HER2-Positive breast and gastric cancers resistant to trastuzumab emtansine","volume":"18","author":"Le Joncour","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.canlet.2025.217900_bib16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.canlet.2019.12.037","article-title":"ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer","volume":"473","author":"Barok","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217900_bib17","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-Positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217900_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102284","article-title":"Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan","volume":"53","author":"Pourjamal","year":"2025","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.canlet.2025.217900_bib19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.217900_bib20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nature24297","article-title":"Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition","volume":"551","author":"Hangauer","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.217900_bib21","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41586-021-03796-6","article-title":"Cycling cancer persister cells arise from lineages with distinct programs","volume":"596","author":"Oren","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.217900_bib22","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-20-1265","article-title":"Ontogeny and vulnerabilities of drug-tolerant persisters in HER2+ breast cancer","volume":"12","author":"Chang","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2025.217900_bib23","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1158\/1535-7163.MCT-23-0578","article-title":"Polyploidy in cancer: causal mechanisms, cancer-specific consequences, and emerging treatments","volume":"23","author":"Conway","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.canlet.2025.217900_bib24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/onc.2013.96","article-title":"Generation of cancer stem-like cells through the formation of polyploid giant cancer cells","volume":"33","author":"Zhang","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2025.217900_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1410637","article-title":"Polyploid giant cancer cells: origin, possible pathways of formation, characteristics, and mechanisms of regulation","volume":"12","author":"Liu","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.canlet.2025.217900_bib26","doi-asserted-by":"crossref","first-page":"R46","DOI":"10.1186\/bcr2868","article-title":"Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo","volume":"13","author":"Barok","year":"2011","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2025.217900_bib27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.canlet.2011.03.002","article-title":"Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer","volume":"306","author":"Barok","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217900_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.617","article-title":"Characterization of T-DM1-resistant breast cancer cells","volume":"8","author":"Sauveur","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.canlet.2025.217900_bib29","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217900_bib30","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.canlet.2025.217900_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2023.102446","article-title":"Protocol for automated multivariate quantitative-image-based cytometry analysis by fluorescence microscopy of asynchronous adherent cells","volume":"4","author":"Besse","year":"2023","journal-title":"STAR Protoc"},{"key":"10.1016\/j.canlet.2025.217900_bib32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13008-018-0039-z","article-title":"Measuring DNA content in live cells by fluorescence microscopy","volume":"13","author":"Gomes","year":"2018","journal-title":"Cell Div."},{"key":"10.1016\/j.canlet.2025.217900_bib33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nmeth.4177","article-title":"Pooled CRISPR screening with single-cell transcriptome readout","volume":"14","author":"Datlinger","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.canlet.2025.217900_bib34","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1053\/j.gastro.2020.01.045","article-title":"Gliadin nanoparticles induce immune tolerance to gliadin in mouse models of celiac disease","volume":"158","author":"Freitag","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2025.217900_bib35","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.cell.2015.05.002","article-title":"Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets","volume":"161","author":"Macosko","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.217900_bib36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-Seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.canlet.2025.217900_bib37","doi-asserted-by":"crossref","first-page":"D766","DOI":"10.1093\/nar\/gky955","article-title":"GENCODE reference annotation for the human and mouse genomes","volume":"47","author":"Frankish","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2025.217900_bib38","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-Seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.canlet.2025.217900_bib39","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1038\/nprot.2014.174","article-title":"Illumina human exome genotyping array clustering and quality control","volume":"9","author":"Guo","year":"2014","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.canlet.2025.217900_bib40","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41467-018-08200-y","article-title":"Exploring the landscape of focal amplifications in cancer using AmpliconArchitect","volume":"10","author":"Deshpande","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2025.217900_bib41","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41586-023-05937-5","article-title":"Extrachromosomal DNA in the cancerous transformation of Barrett's oesophagus","volume":"616","author":"Luebeck","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.217900_bib42","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1038\/s41596-018-0052-3","article-title":"Discovery of potential causative mutations in human coding and noncoding genome with the interactive software BasePlayer","volume":"13","author":"Katainen","year":"2018","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.canlet.2025.217900_bib43","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.cell.2020.11.018","article-title":"Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy","volume":"184","author":"Rehman","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.217900_bib44","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cancergencyto.2006.09.014","article-title":"Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1","volume":"172","author":"Rennstam","year":"2007","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.canlet.2025.217900_bib45","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/s41586-023-06057-w","article-title":"ERalpha-associated translocations underlie oncogene amplifications in breast cancer","volume":"618","author":"Lee","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.217900_bib46","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.88895","article-title":"Transcriptional immune suppression and up-regulation of double-stranded DNA damage and repair repertoires in ecDNA-containing tumors","volume":"12","author":"Lin","year":"2024","journal-title":"eLife"},{"key":"10.1016\/j.canlet.2025.217900_bib47","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41576-022-00521-5","article-title":"Extrachromosomal DNA amplifications in cancer","volume":"23","author":"Yi","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.canlet.2025.217900_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.567116","article-title":"Polyploid giant cancer cells, a hallmark of oncoviruses and a new therapeutic challenge","volume":"10","author":"Herbein","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2025.217900_bib49","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ebiom.2018.03.015","article-title":"The human cytomegalovirus strain DB activates oncogenic pathways in mammary epithelial cells","volume":"30","author":"Kumar","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.canlet.2025.217900_bib50","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.tcb.2020.06.006","article-title":"Polyploidy: a biological force from cells to ecosystems","volume":"30","author":"Fox","year":"2020","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.canlet.2025.217900_bib51","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.semcancer.2020.11.016","article-title":"Cancer cells employ an evolutionarily conserved polyploidization program to resist therapy","volume":"81","author":"Pienta","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.canlet.2025.217900_bib52","doi-asserted-by":"crossref","first-page":"484","DOI":"10.4161\/cc.7.4.5316","article-title":"Cells enter a unique intermediate 4N stage, not 4N-G1, after aborted mitosis","volume":"7","author":"Mantel","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canlet.2025.217900_bib53","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s40265-021-01614-x","article-title":"Disitamab vedotin: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.canlet.2025.217900_bib54","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.217900_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1220589","article-title":"Giant cells: multiple cells unite to survive","volume":"13","author":"Hazra","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.canlet.2025.217900_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24010096","article-title":"MHY440, a novel topoisomerase iota inhibitor, induces cell cycle arrest and apoptosis via a ROS-dependent DNA damage signaling pathway in AGS human gastric cancer cells","volume":"24","author":"Jang","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.canlet.2025.217900_bib57","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2025.217900_bib58","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/cdd.2008.47","article-title":"Death through a tragedy: mitotic catastrophe","volume":"15","author":"Vakifahmetoglu","year":"2008","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2025.217900_bib59","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/bcr3621","article-title":"Trastuzumab emtansine: mechanisms of action and drug resistance","volume":"16","author":"Barok","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2025.217900_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102418","article-title":"Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: a systematic review","volume":"108","author":"Blange","year":"2022","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.canlet.2025.217900_bib61","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1158\/1078-0432.CCR-24-3468","article-title":"Human epidermal growth factor receptor 2 loss following treatment with trastuzumab deruxtecan in patients with metastatic breast cancer","volume":"31","author":"Gouda","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.217900_bib62","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1126\/science.1241328","article-title":"Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA","volume":"343","author":"Nathanson","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.canlet.2025.217900_bib63","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55460-9","article-title":"Nectin-4 cis-interacts with ErbB2 and its trastuzumab-resistant splice variants, enhancing their activation and DNA synthesis","volume":"9","author":"Kedashiro","year":"2019","journal-title":"Sci. Rep."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525004689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525004689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T23:05:02Z","timestamp":1760742302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525004689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":63,"alternative-id":["S0304383525004689"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217900","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-tolerant persisting polyploid giant cancer cells mediate resistance to HER2-targeting antibody-drug conjugates","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217900","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"217900"}}